Aspartic protease inhibitors. An integrated approach for the design and synthesis of diaminodiol-based peptidomimetics

European Journal of Biochemistry

Volumn 267, Issue 6, 2000, Pages 1715-1722

  Tossi, Alessandro ^c   Bonin, Irena ^a   Antcheva, Nikolinka ^c   Norbedo, Stefano ^c   Benedetti, Fabio ^c   Miertus, Stanislav ^a   Nair, Anil C ^b   Maliar, Tibor ^b   Dal Bello, Federico ^c   Palù, Giorgio ^c   Romeo, Domenico ^c  

^a UNIDO   (Italy)

^b POLYtech   (Italy)

^c NONE

Author keywords

Computational studies; Diaminodiol inhibitors; HIV 1 protease; Peptide synthesis; Pseudopeptides

Indexed keywords

A 76889; A 76928; A 77003; ASPARTIC PROTEINASE INHIBITOR; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COMPLEX FORMATION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; PRIORITY JOURNAL; REACTION ANALYSIS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DIAMINES; DRUG DESIGN; HIV PROTEASE INHIBITORS; HIV-1; MODELS, CHEMICAL; MODELS, MOLECULAR; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034022976     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1327.2000.01164.x     Document Type: Article

References (36)

1. 1. Babine, R. & Bender, S. (1997) Molecular recognition of protein-ligand complexes: applications to drug design. Chem. Rev. 97, 1359-1472.
2. 2. Takahashi, K., ed. (1994) Aspartic proteinases: structure, function, biology and biomedical implications. Adv. Exp. Med. Biol. 362.
3. 3. James, M.N., ed. (1998) Aspartic proteinases: retroviral and cellular enzymes. Adv. Exp. Med. Biol. 436.
4. 4. Hoover, D.J., Lefker, B.A., Rosati, R.L., Wester, R.T., Kleinman, E.F., Bindra, J.S., Holt, W.F., Murphy, W.R., Mangiapane, M.L., Hockel, G.M., Williams, I.H., Smith, W.H., Gumkowski, M.J., Shepard, R.M., Gardner, M.J. & Nocerini, M.R. (1995) Discovery of inhibitors of human renin with high oral bioavailability. Adv. Exp. Med. Biol. 362, 167-180.
5. 5. West, M.L. & Fairlie, D.P. (1995) Targeting HIV-1 protease: a test of drug-design methodologies. Trends Pharm. Sci. 16, 67-75.
6. 6. Kempf, D.J. & Sham, H.L. (1996) HIV protease inhibitors. Curr. Pharmac. Design 2, 225-246.
7. 7. Martin, J.A., Redshaw, S. & Thomas, G.J. (1995) Inhibitors of HIV proteinase. Prog. Med. Chem. 32, 239-287.
8. 8. Moyle, G. & Gazzard, D. (1996) Current knowledge and future prospects for the use of HIV-I protease inhibitors. Drugs 51, 701-712.
9. 9. Goldman, R.C., Frost, D.J., Capobianco, J.O., Kadam, S., Rasmussen, R.R. & Abad-Zapatero, C. (1995) Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis. Infect. Agents Dis. 4, 228-247.
10. 10. Rosenthal, P.J. (1998) Proteases of malaria parasites: new targets for chemotherapy. Emerg. Infect. Dis. 4, 49-57.
11. 11. Benedetti, F., Miertus, S., Norbedo, S., Tossi, A. & Zlatoidsky, P. (1997) Versatile and stereoselective synthesis of diamino diol dipeptide isosteres, core units of pseudopeptide HIV protease inhibitors. J. Org. Chem. 62, 9348-9353.
12. 12. Tossi, A., Antcheva, N., Benedetti, F., Norbedo, S., Miertus, S. & Romeo, D. (1999) Flexible synthesis of symmetric and non-symmetric HIV-1 protease inhibitors based on all-S-diaminodiol isosteres. Peptide Protein Lett. 6, 145-148.
13. 13. Tossi, A., Antcheva, N., Romeo, D. & Miertus, S. (1995) Development pseudopeptide inhibitors of HIV-1 aspartic protease: analysis and tuning of the subsite specificity. Peptide Res. 8, 2-8.
14. 14. Miertus, S., Furlan, M., Tossi, A. & Romeo, D. (1996) Design of new inhibitors of HIV-1 aspartic protease. Chem. Phys. 204, 173-180.
15. 15. Nair, C.A., Miertus, S., Tossi, A. & Romeo, D. (1998) A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues. Biochem. Biophys. Res. Commun. 242, 545-551.
16. 2 symmetric inhibitors of HIV-1 protease. J. Med. Chem. 33, 2687-2689.
17. 17. Chenera, B., Boehm, J.C. & Dreyer, G.B. (1991) Synthesis of C-2-symmetric and pseudosymmetric HIV-1 protease inhibitors from D-mannitol and D-arabitol. Bioorg. Med. Chem. Lett. 1, 219-222.
18. 18. Ghosh, A.K., McKee, S.P. & Thompson, W.J. (1991) Stereocontrolled synthesis of HIV-1 protease inhibitors with C2 axis of symmetry. Tetrahedron Lett. 32, 5729-5732.
19. 2-symmetric diamino alcohols and diols for use in HIV protease inhibitors. J. Org. Chem. 57, 5692-5700.
20. 6]. Synthesis of C2-symmetric (1S,2R,3R,4S)-1,4-diamino-2,3-diols. J. Org. Chem. 57, 28-32.
21. 2 symmetric meso-amino alcohol. J. Chem. Soc. Chem. Commun. 355-356.
22. 2-symmetric based diols, epoxides and dideoxy derivatives of HIV protease. Tetrahedron 53, 4769-4778.
23. 23. Benedetti, F., Berti, F. & Norbedo, S. (1998) Regio-and stereoselective ring opening of 2,3-epoxyalcohols with diethylaluminium azide. Tetrahedron Lett. 39, 7971-7974.
24. 24. Wang, Y.X., Freedberg, D.I., Yarnazki, T., Wingfield, P.T., Stahl, S.J., Kaufman, J.D., Kiso, Y. & Torchia, D.A. (1996) Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Biochemistry 35, 9945-9950.
25. 25. Miertus, S., Antcheva, N., Tossi, A., Bizik, F., Benedetti, F., Gennaro, R. & Romeo, D. (1995) CADD of new pseudopeptide inhibitors of HIV-1 aspartic protease. In QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications (Sanz, F., Giraldo J. & Manaut, F., eds.), pp. 567-572. Prous Science Publishers, Barcelona, Spain.
26. 26. Mitin, Y. (1996) An effective organic solvent system for the dissolution of amino acids. Int. J. Peptide Protein Res. 48, 374-376.
27. 27. Maschera, B., Furfine, E. & Blair, E.D. (1995) Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69,5431-5436.
28. 28. Meylan, W.H. & Howard, P.H. (1995) Atom/fragment contribution method for estimating octanol/water partition coefficients. J. Pharm. Sci. 84, 83-92.
29. 29. Kempf, D.J. (1994) Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease. Methods Enzymol. 241, 334-354.
30. 2 symmetry-based diol inhibitors of HIV-1 protease. J. Am. Chem. Soc. 116, 847-855.
31. 31. Budt, K.-H., Peyman, A., Hansen, J., Knolle, J., Meichsner, C., Paessens, A., Ruppert, D. & Stowasser, B. (1995) HIV-1 protease inhibitor HOE/BAY 793, structure - activity relationships in a series of C-2-symmetric diols. Bioorg. Med. Chem. 3, 559-571.
32. 32. Kempf, D.J., Codacovi, L., Wang, X.C., Kohlbrenner, W.E., Wideburg, N.E., Saldivar, A., Vasavanonda, S., Marsh, K.C., Bryan, P., Sham, H.L., Green, B.E., Betebenner, D.A., Erickson, J. & Norbeck, T.W. (1993) Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane. J. Med. Chem. 36, 320-330.
33. 33. Dreyer, G.B., Boehm, J.C., Chenera, B., DesJarlais, R.L., Hassell, A.M., Meek, T.D. & Tomaszek, T.A. (1993) A symmetric inhibitor binds HIV-1 protease asymmetrically. Biochemistry 32, 937-947.
34. 34. Dunn, B., Gustchina, A., Vlodawer, A. & Kay, J. (1994) Subsite preferences of retroviral proteinases. Methods Enzymol. 241, 254-278.
35. 35. Lange-Savage, G., Berchtold, H., Liesum, A., Budt, K.H., Peyman, A., Knolle, J., Sedlacek, J., Fabry, M. & Hilgenfeld, R. (1997) Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms. Structure/function relationship and influence of crystal packing. Eur. J. Biochem. 248, 313-322.
36. 36. Karajiannis, H. & van de Waterbeemd, H. (1995) The prediction of the lipophilicity of peptidomimetics. A comparison between experimental and theoretical lipophilicity values of renin inhibitors and their building blocks. Pharmaceutica Acta Helvetiae 70, 67-77.